A. Keith Stewart, MB, ChB: Outcomes for multiple myeloma patients have improved dramatically over the past decade. This has come about as the result of the introduction of a whole new class of novel ...
Combination therapies in multiple myeloma show superior efficacy over monotherapies, with higher response rates and progression-free survival. Monotherapy with agents like Empliciti and Darzalex shows ...
MIT researchers have developed a new theoretical framework for studying the mechanisms of treatment interactions. Their approach allows scientists to efficiently estimate how combinations of ...
Amrita Krishnan, MD, FACP: The ALCYONE trial, which was recently published in the New England Journal of Medicine, of daratumumab/bortezomib/melphalan/prednisone, or ...
Patients with relapsed or refractory (R/R) multiple myeloma who received a combination of teclistamab, a bispecific monoclonal antibody, and daratumumab, a CD38-directed monoclonal antibody, were 83% ...
A randomized phase 2, multicenter, open-label study of trastuzumab deruxtecan (DS-8201a) in subjects with HER2-expressing gastric cancer. Background: Multiple cancers have been treated successfully ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results